Profile data is unavailable for this security.
About the company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
- Revenue in USD (TTM)331.41m
- Net income in USD-226.54m
- Incorporated1991
- Employees536.00
- LocationBioCryst Pharmaceuticals Inc4505 Emperor Blvd Ste 200DURHAM 27703-8457United StatesUSA
- Phone+1 (919) 859-1302
- Fax+1 (919) 859-1314
- Websitehttps://www.biocryst.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
USANA Health Sciences, Inc. | 921.01m | 63.79m | 798.87m | 1.80k | 12.59 | 1.60 | 10.44 | 0.8674 | 3.30 | 3.30 | 47.61 | 25.99 | 1.50 | 2.75 | -- | 511,672.20 | 10.38 | 16.23 | 13.20 | 21.75 | 80.82 | 81.42 | 6.93 | 8.96 | 3.00 | -- | 0.0016 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
89bio Inc | 0.00 | -142.19m | 810.36m | 70.00 | -- | 1.48 | -- | -- | -2.01 | -2.01 | 0.00 | 5.75 | 0.00 | -- | -- | 0.00 | -35.86 | -45.50 | -38.49 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0442 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
SS Innovations International Inc | 5.88m | -20.94m | 810.94m | 239.00 | -- | 56.71 | -- | 137.92 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Enliven Therapeutics Inc | 0.00 | -71.58m | 812.20m | 46.00 | -- | 2.92 | -- | -- | -2.18 | -2.18 | 0.00 | 5.95 | 0.00 | -- | -- | 0.00 | -40.31 | -42.26 | -44.80 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
National Research Corporation | 148.58m | 30.96m | 817.60m | 435.00 | 27.27 | 16.94 | 22.17 | 5.50 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
Tango Therapeutics Inc | 36.53m | -101.74m | 821.73m | 140.00 | -- | 3.11 | -- | 22.50 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
SAGE Therapeutics Inc | 91.06m | -503.14m | 837.89m | 487.00 | -- | 1.19 | -- | 9.20 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Immunome Inc | 14.02m | -106.81m | 839.30m | 55.00 | -- | 5.07 | -- | 59.87 | -3.33 | -3.33 | 0.7064 | 2.77 | 0.1625 | -- | -- | 254,872.70 | -123.77 | -94.54 | -148.94 | -112.66 | -- | -- | -761.92 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
ARS Pharmaceuticals Inc | 30.00k | -54.37m | 842.98m | 24.00 | -- | 3.63 | -- | 28,099.38 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Viridian Therapeutics Inc | 314.00k | -237.73m | 846.29m | 96.00 | -- | 3.04 | -- | 2,695.18 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
OPKO Health Inc | 863.49m | -188.86m | 850.33m | 3.93k | -- | 0.6791 | -- | 0.9848 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
BioCryst Pharmaceuticals Inc | 331.41m | -226.54m | 851.40m | 536.00 | -- | -- | -- | 2.57 | -1.18 | -1.18 | 1.72 | -2.21 | 0.6212 | 0.1658 | 6.16 | 618,306.00 | -42.46 | -47.95 | -55.84 | -64.89 | 98.59 | 97.06 | -68.36 | -114.94 | 3.12 | -1.11 | 2.19 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
ALX Oncology Holdings Inc | 0.00 | -160.81m | 859.49m | 72.00 | -- | 4.48 | -- | -- | -3.74 | -3.74 | 0.00 | 3.80 | 0.00 | -- | -- | 0.00 | -58.58 | -34.34 | -66.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0592 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Relay Therapeutics Inc | 25.55m | -341.97m | 862.82m | 323.00 | -- | 1.11 | -- | 33.78 | -2.79 | -2.79 | 0.2095 | 5.90 | 0.0263 | -- | 9.79 | 79,089.78 | -35.19 | -28.55 | -36.97 | -29.54 | -- | -- | -1,338.66 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Bicycle Therapeutics PLC (ADR) | 26.98m | -180.66m | 890.33m | 284.00 | -- | 2.68 | -- | 33.00 | -5.13 | -5.13 | 0.7585 | 8.74 | 0.0536 | -- | 26.38 | 94,985.91 | -35.92 | -29.45 | -40.92 | -32.98 | -- | -- | -669.72 | -571.36 | -- | -- | 0.0764 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Tyra Biosciences Inc | 0.00 | -69.13m | 898.16m | 49.00 | -- | 3.60 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 17.26m | 8.37% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 15.75m | 7.64% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 13.05m | 6.33% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 12.78m | 6.20% |
Baker Bros. Advisors LPas of 31 Dec 2023 | 10.13m | 4.91% |
Braidwell LPas of 31 Dec 2023 | 5.72m | 2.77% |
Kynam Capital Management LPas of 31 Dec 2023 | 4.60m | 2.23% |
Geode Capital Management LLCas of 31 Dec 2023 | 4.26m | 2.07% |
RP Management LLC (Investment Management)as of 31 Dec 2023 | 3.85m | 1.87% |
Rock Springs Capital Management LPas of 31 Dec 2023 | 3.27m | 1.59% |